Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

Walter Reed Army Medical Center43 enrolled

Overview

The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.

This is a prospective randomized double blind trial of patients undergoing selective laser trabeculoplasty for primary open angle glaucoma and ocular hypertension. Enrolled patients are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of apraclonidine 0.5% in the fellow eye. The trabecular meshwork in both eyes of each enrolled patient is treated 360 degrees at the same sitting. Intraocular pressure is measured in each eye one hour before applying the study medications and at one hour and one week after laser surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Glaucoma Ocular Hypertension

Interventions

brimonidine 0.1%DRUG

1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)

Apraclonidine 0.5%DRUG

1 drop applied 1 hour prior to SLT

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male or female, at least 18 years of age * Open Angle Glaucoma with inadequate intraocular pressure (IOP) control or evidence of progression (based on optic nerve head appearance and/or visual field changes) despite current medical therapy * Ocular Hypertension requiring lowering of IOP * ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits Exclusion Criteria: * inability to understand and provide informed consent to participate in this study * inability/unwillingness to follow study instructions and complete all required visits * Documented allergy to either brimonidine or iopidine * Angle Closure Glaucoma * Congenital/Juvenile Glaucoma * Neovascular Glaucoma * Active uveitis

Locations (1)

Walter Reed Army Medical Center

Washington D.C., District of Columbia, United States

RECRUITING

Outcomes

Primary Outcomes

Postoperative IOP

Time frame: 1 hour and 1 week post surgery

Secondary Outcomes

Overall IOP reduction post SLT

Time frame: 1 month

Central Contacts

Vladimir S Yakopson, MD

CONTACT

202-782-6965 vladimir.yakopson@na.amedd.army.mil

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.